BerGenBio Announces Abstracts Accepted for Presentation at 2023 ASCO
- Oral presentation to reveal data from trial evaluating bemcentinib in relapsed mesothelioma -
- Trial-in-Progress poster to be presented regarding the BGBC016 1L STK11m NSCLC trial -
BERGEN, Norway, May 25, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that the Company will be presenting two abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago June 2-6, 2023.
An oral presentation will highlight the results of MIST3, an investigator led, multi-center Phase IIa study led by Professor Dean Fennell at the University of Leicester, UK that assessed the use of bemcentinib in combination with pembrolizumab in patients with relapsed mesothelioma.
A Trial-in-Progress poster will outline the plans for the ongoing BGBC016 Phase 1b/2a study evaluating bemcentinib in combination with pembrolizumab and chemotherapy in 1L STK11m NSCLC patients.
The abstracts will be available in Scientific Presentations on the Company’s website shortly after their presentations at the conference.
ASCO Abstract Details:
Oral Presentation
Abstract Number: 8511
Abstract Session: Lung Cancer
Presenter: Matthew Krebs, Ph.D., FRCP, Christie Hospital, Manchester, UK
Date/Time: Monday 5th June, 11.30am – 1.00pm
Poster Presentation
Abstract Number: TPS9154
Poster Number: 134b
Abstract Session: Lung Cancer – Non-Small Cell Metastatic
Presenter: Rajwanth Veluswamy, MD, MSCR, Mount Sinai, New York, NY
Date/Time: Sunday 4th June 8.00am-11.00am
-End-
Contacts
Martin Olin CEO, BerGenBio ASA
Rune Skeie, CFO, BerGenBio ASA
Investor Relations
Graham Morrell
Media Relations
Jan Lilleby
+47 90 55 16 98
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.